Next Show for Prolia

After last week's FDA approval of Prolia denosumab from Amgen Inc. to treat postmenopausal osteoporosis, buysiders are focused on upcoming data and an approval in oncology, which they expect could be a more lucrative market due higher dosing and more frequent treatment.

First up are Phase III data to prevent or delay bone metastases in prostate cancer patients. Results are expected next half. Next is an anticipated approval late this year or early next for Prolia to reduce skeletal related events (SREs) in cancer patients. Amgen (NASDAQ:AMGN) submitted a BLA to FDA for that indication last month (see BioCentury, May 17). ...